Drug Manufacturers - Specialty & Generic — industry outlook

Period: 2026-08-30 to 2026-09-20
Events: 16
Generated: 2026-09-20T06:30:00.003Z

Financial Guidance and Revenue Trajectories

Multiple companies have updated forward-looking revenue and margin expectations, with Teva (TEVA) accelerating its OSTEDO trajectory to exceed $3 billion by 2027 and reaching $800 million in biosimilar revenue by 2026, a year ahead of schedule. Teva (TEVA) also targets a cumulative $1.5 billion to $2 billion peak sales figure for Yosedi and Olanzapine by the end of the decade, while aiming for $2.5 billion in OSTEDO sales in 2026 to be met one year early. In contrast, Zoetis (ZTS) forecasts a full-year operational revenue decline of -3% to -1%, with net price realization dropping -1% to -2% in the current year, though it expects market stabilization and a return to growth by late 2026. Prestige Consumer Healthcare (PBH) projects top-line sales growing approximately 10% over the next three years (2026–2028) to reach $1.4 billion in pro forma sales, aiming to generate $900 million in free cash flow during that period to deleverage. Collegium Pharmaceutical (COLL) raised its 2026 revenue guidance to $825–$855 million (up 8% YoY), with a target to exceed $1 billion in revenue, maintaining EBITDA margins above 50%. Elanco Animal Health (ELAN) targets 5–6 new blockbuster products by 2031 and a path to 60% gross margins by 2027, while Amphastar (AMPH) expects mid-to-high single-digit revenue growth in 2026 and 2027, targeting $250–$275 million in peak annual sales for Baximi.

Pricing, Reimbursement, and Regulatory Headwinds

Medicare Part D statutory changes and Maximum Fair Price (MFP) mechanisms are identified as primary pricing risks, with Neurocrine Biosciences (NBIX) noting a 2% to 5% rebate increase starting in 2027 and potential revenue dips in 2029 due to MFP implementation. Teva (TEVA) faces significant hurdles regarding Olanzapine access, with Medicaid being the primary rate-limiting step for the first year due to state-by-state variations, while Medicare access is delayed in Year 1. Zoetis (ZTS) anticipates 20–40% structural price erosion over 2–3 years for products like Convenia and Serena, reflecting ongoing discounting pressure, though it views the broader pet care decline as cyclical rather than structural. Amphastar (AMPH) expects to resolve double-discounting issues in the 340B program by Q4 2026, which is critical for restoring volume growth for Baximi. Prestige Consumer Healthcare (PBH) faces continued regulatory scrutiny and facility inspections that have constrained supply for its Clear Eyes franchise, with recovery expected in the back half of Fiscal 2027.

Therapeutic Portfolio Growth and Launch Cadences

Companies are pivoting toward specific high-growth therapeutic areas, with Teva (TEVA) focusing on CNS and immunology, targeting the launch of Olanzapine in Q4 2026/early 2027 to cover 85% of the schizophrenia population and Ecopipam for Tourette's in the first half of 2027. Neurocrine Biosciences (NBIX) is advancing a diversified pipeline, with Phase 3 data expected for Osovampitor in 2027 and Doreclidine in 2027–2028, while maintaining a $750 million run rate for Kinessity. Collegium Pharmaceutical (COLL) is expanding its ADHD portfolio via the acquisition of Astaris, targeting 27,000 prescribers and expecting the combined franchise to drive growth toward a $1 billion revenue milestone. Elanco (ELAN) is launching Bifrena in Q4 2024 with a ramp to 2027, and plans to submit a clean label improvement for Zinrelia at the end of 2024, with FDA feedback expected in mid-2027. Prestige Consumer Healthcare (PBH) is shifting Breathe Right into a "wellness" category and capitalizing on GLP-1 side effects to drive demand for Fleet products. Amphastar (AMPH) plans to launch AMP018 (a GLP-1 generic) and AMP004 (insulin aspart) in 2027.

Strategic M&A, Innovation, and Pipeline Expansion

Mergers and acquisitions are central to near-term growth strategies, with Teva (TEVA) anticipating a deal with Amalex and potentially BioXcel, while Collegium (COLL) completed its Astaris acquisition to create a complementary ADHD portfolio. Prestige Consumer Healthcare (PBH) is integrating recent acquisitions including Breathe Right, Lacorium, and Pillar 5, aiming to return to the higher end of its organic growth range once supply stabilizes. Evotec (EVO) is shifting to an asset-light model for its Jeb business, with technology licensing revenue expected to ramp up after 12 months. BioAge Labs (BIOA) is pausing Phase 3 ASCVD trials pending further data clarity from Artemis and Zeus trials, pivoting focus to ophthalmology and metabolic indications like DME and obesity. Neurocrine (NBIX) is integrating Soleno/Vicat-XR assets to drive growth post-integration and plans to reinvest 30–35% of cash flows into its pipeline.

Operational Execution and Supply Chain Dynamics

Supply chain constraints and manufacturing capacity are critical bottlenecks for several firms. Zoetis (ZTS) expects share shifts in the parasiticide market to stabilize over an 18-month horizon, while Elanco (ELAN) forecasts supply constraints for Bifrena will persist through H1 2027 before demand is met. Amphastar (AMPH) is reallocating CapEx to modernize clean rooms at its IMS facility following warning letters, with short-term slowdowns expected. Teva (TEVA) notes that its Olanzapine launch is contingent on overcoming Medicaid access hurdles, while Collegium (COLL) aims to eliminate Nusenta price erosion post-authorized generic launch in Q1 2026. BioAge Labs (BIOA) emphasizes the need for de-risked clinical data in ophthalmology to validate its oral NLRP3 inhibitor approach, contrasting with its previous reliance on cardiovascular outcomes. Teva (TEVA) also highlighted a potential competitive advantage in U.S. manufacturing amidst proposed 100% tariffs on imported generics starting August 2028, while Zoetis (ZTS) views current market headwinds as cyclical, expecting the U.S. pet care market to return to growth coincident with share stabilization.